The Performance of Renal Doppler Ultrasound in Predicting Outcome of Dialysis Weaning

March 20, 2024 updated by: Johan Fridolf Hermansen

Acute kidney injury (AKI) is a frequent problem in the intensive care unit (ICU) affecting more than 50 % of patients. AKI is associated with several adverse outcomes, including increased mortality and increased length of ICU- and hospital stay, in particular in patients requiring Renal Replacement Therapy (RRT).

Choosing the optimal time for attempting liberation from RRT is still unclear. With this study, we will describe the ability of renal ultrasound in predicting the outcome of dialysis weaning.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

33

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Denmark
      • Aarhus, Denmark, 8200
        • Aarhus University Hospital, Department of Anaesthesiology

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients admitted to the ICU, Aarhus University Hospital who are treated with dialysis as CRRT and planned to undergo dialysis weaning as determined their attending ICU physician.

Description

Inclusion Criteria:

  • All patients ≥ 18 years admitted to the ICU, Aarhus University Hospital who are treated with dialysis as continuous renal placement therapy (CRRT) and planned to undergo dialysis weaning

Exclusion Criteria:

  • Insufficient ultrasonographic imaging of the kidneys
  • Known morphological kidney disease
  • Previous need of chronic RRT
  • Prior participation in the study
  • Need of extracorporeal membrane oxygenation (ECMO) or other heart assist device

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
ICU patients
Patients who are treated with dialysis as CRRT and planned to undergo dialysis weaning.
Other: Dialysis weaning
Dialysis weaning as planned by the attending ICU-physician.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Dialysis weaning
Time Frame: 7 days
If discontinuation of Dialysis is successful or not. Successful dialysis weaning is defined as no renal replacement therapy (RRT) required within the first 7 days after stopping continuous renal replacement therapy (CRRT) and non-successful weaning as the need for RRT within the first 7 days.
7 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Renal Doppler arterial Resistive Index (RI)
Time Frame: Measured at the beginning of weaning and after 6 hours.
Measured in the interlobar vessels
Measured at the beginning of weaning and after 6 hours.
Renal Doppler Renal Venous Stasis Index (RVSI)
Time Frame: Measured at the beginning of weaning and after 6 hours.
Measured in the interlobar vessels
Measured at the beginning of weaning and after 6 hours.
Renal Doppler Venous Impedance Index (VII)
Time Frame: Measured at the beginning of weaning and after 6 hours.
Measured in the interlobar vessels
Measured at the beginning of weaning and after 6 hours.
Portal vein Doppler Pulsatility Fraction PF)
Time Frame: Measured at the beginning of weaning and after 6 hours.
Measured in the interlobar vessels
Measured at the beginning of weaning and after 6 hours.
Urine Output
Time Frame: 4 days
4 days
Urine Creatinine Clearance
Time Frame: 4 days
4 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Johan Fridolf Hermansen

Investigators

  • Study Chair: Peter Juhl-Olsen, MD, PhD, Aarhus University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2021

Primary Completion (Actual)

March 1, 2023

Study Completion (Actual)

March 1, 2023

Study Registration Dates

First Submitted

October 26, 2020

First Submitted That Met QC Criteria

November 5, 2020

First Posted (Actual)

November 10, 2020

Study Record Updates

Last Update Posted (Actual)

March 21, 2024

Last Update Submitted That Met QC Criteria

March 20, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1-10-72-40-20(3)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe